Gavin Phd Giovannoni

Gavin Phd Giovannoni's AcademicInfluence.com Rankings

Medical

#1124

World Rank

#1431

Historical Rank

Neurology

#104

World Rank

#159

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Gavin Phd Giovannoni Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Gavin Phd Giovannoni's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. (2006) (2970)
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. (2012) (1465)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (2017) (1170)
Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis (2017) (1107)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial (2012) (1044)
A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. (2010) (819)
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. (2010) (708)
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. (2000) (642)
Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease (2012) (618)
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking (2009) (618)
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases (2010) (615)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study (2018) (559)
Multiple sclerosis – a review (2018) (550)
Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. (2005) (528)
Multiple sclerosis: risk factors, prodromes, and potential causal pathways (2010) (490)
Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies (2000) (474)
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study (2009) (435)
Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases (2013) (365)
Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells (2007) (340)
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. (2003) (337)
The therapeutic potential of cannabis (2003) (326)
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS (2007) (317)
Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. (2004) (312)
Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude (2013) (299)
An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis (2010) (291)
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial (2013) (285)
Brain health: time matters in multiple sclerosis. (2016) (269)
Infectious causes of multiple sclerosis (2006) (269)
Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force (2006) (262)
Environmental factors and their timing in adult-onset multiple sclerosis (2010) (262)
The incidence and significance of anti-natalizumab antibodies (2007) (260)
Is it time to target no evident disease activity (NEDA) in multiple sclerosis? (2015) (257)
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study (2015) (255)
Anti–basal ganglia antibodies in acute and persistent Sydenham’s chorea (2002) (254)
Smoking and Multiple Sclerosis: An Updated Meta-Analysis (2011) (245)
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab (2012) (239)
Neurofilament light chain (2015) (222)
Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. (2002) (219)
The evidence for a role of B cells in multiple sclerosis (2012) (211)
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis (2011) (205)
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis (2010) (200)
Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study (2018) (193)
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis (2017) (192)
Health‐related quality of life in multiple sclerosis: effects of natalizumab (2007) (190)
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI (2009) (188)
Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab (2017) (187)
Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto‐reactive antibasal ganglia antibodies (2001) (186)
Human Endogenous Retroviruses in Neurological Diseases (2018) (180)
Multiple sclerosis: the environment and causation (2007) (175)
Alemtuzumab CARE-MS II 5-year follow-up (2017) (174)
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis (2011) (172)
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis (2015) (168)
Tourette’s syndrome: a cross sectional study to examine the PANDAS hypothesis (2003) (166)
Adaptation of the Nitrate Reductase and Griess Reaction Methods for the Measurement of Serum Nitrate plus Nitrite Levels (1997) (161)
Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial (2016) (159)
The COVID-19 pandemic and the use of MS disease-modifying therapies (2020) (157)
Optimizing treatment success in multiple sclerosis (2015) (154)
A specific ELISA for measuring neurofilament heavy chain phosphoforms. (2003) (149)
The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude (2012) (149)
Serum neurofilament is associated with progression of brain atrophy and disability in early MS (2017) (147)
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis (2015) (146)
Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. (2009) (144)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL (2009) (139)
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials (2020) (137)
The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis (2013) (136)
Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies (2019) (136)
Matrix metalloproteinases in inflammatory demyelination (1999) (136)
Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome (2014) (135)
Month of birth, vitamin D and risk of immune-mediated disease: a case control study (2012) (133)
Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study (2005) (133)
Alemtuzumab CARE-MS I 5-year follow-up (2017) (132)
COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases (2020) (130)
Fingolimod modulates microglial activation to augment markers of remyelination (2011) (129)
Association of innate immune activation with latent Epstein-Barr virus in active MS lesions (2012) (127)
Trial of Fingolimod versus Interferon Beta‐1a in Pediatric Multiple Sclerosis (2018) (127)
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis (2007) (127)
Immunopathogenic mechanisms in tourette syndrome: A critical review (2009) (126)
Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence (2012) (124)
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome (2015) (123)
A comparative study of CSF neurofilament light and heavy chain protein in MS (2013) (120)
“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis (2017) (119)
CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis (2004) (118)
Myasthenia gravis and neuromyelitis optica spectrum disorder (2012) (117)
Cerebrospinal fluid biomarkers in multiple sclerosis (2009) (116)
Neuronal surface glycolytic enzymes are autoantigen targets in post-streptococcal autoimmune CNS disease (2006) (115)
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study (2011) (114)
Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. (2008) (113)
The potential role of nitric oxide in multiple sclerosis (1998) (110)
Bradykinesia akinesia inco-ordination test (BRAIN TEST): an objective computerised assessment of upper limb motor function (1999) (104)
Raised serum nitrate and nitrite levels in patients with multiple sclerosis (1997) (103)
UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines (2019) (100)
Incidence of anti-brain antibodies in children with obsessive-compulsive disorder. (2005) (99)
Relationship of UV exposure to prevalence of multiple sclerosis in England (2011) (99)
Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells (2018) (98)
Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm (2018) (98)
Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. (2009) (97)
Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis (2008) (97)
Association of Infectious Mononucleosis with Multiple Sclerosis (2009) (96)
Multiple sclerosis (2003) (96)
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis (2011) (96)
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial (2014) (96)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL (2009) (94)
Multiple sclerosis: a practical overview for clinicians. (2010) (94)
PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results (2013) (93)
Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis (2005) (92)
Cladribine to Treat Relapsing Forms of Multiple Sclerosis (2017) (92)
Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. (2017) (91)
Neurofilament ELISA validation. (2010) (90)
The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis (2013) (90)
Anti-basal ganglia antibodies: a possible diagnostic utility in idiopathic movement disorders? (2004) (89)
Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group. (2018) (88)
Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis (2001) (88)
Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study (2014) (87)
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS (2016) (87)
Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients (2002) (87)
No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis (2014) (86)
Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK (2012) (85)
Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. (2015) (85)
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis (2013) (84)
Cerebrospinal fluid and serum nitric oxide metabolites in patients with multiple sclerosis (1998) (84)
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial (2019) (83)
Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. (2019) (82)
Longitudinal study of soluble adhesion molecules in multiple sclerosis (1997) (82)
Breastfeeding and multiple sclerosis relapses: a meta-analysis (2012) (80)
The PANDAS subgroup of tic disorders and childhood-onset obsessive-compulsive disorder. (2009) (79)
Neutralising antibodies to interferon beta during the treatment of multiple sclerosis (2002) (78)
An ELISA for glial fibrillary acidic protein. (2004) (78)
Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results (2008) (76)
Dyskinesias and associated psychiatric disorders following streptococcal infections (2004) (76)
CSF and serum immune parameters in Sydenham's chorea: evidence of an autoimmune syndrome? (2003) (76)
The Multiple Sclerosis Care Unit (2018) (74)
EFNS guidelines on disease‐specific CSF investigations (2009) (74)
Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. (1997) (74)
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial (2020) (73)
Genetic and environmental factors and the distribution of multiple sclerosis in Europe (2010) (73)
Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. (2019) (73)
Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis (2005) (73)
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial (2020) (73)
HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study (2014) (71)
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS (2012) (71)
Serum autoantibodies do not differentiate PANDAS and Tourette syndrome from controls (2006) (69)
Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. (1996) (69)
Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers (2019) (68)
Fatigue is not associated with raised inflammatory markers in multiple sclerosis (2001) (68)
National survey of UK medical students on the perception of neurology (2014) (68)
Multiple Sclerosis Cerebrospinal Fluid Biomarkers (2006) (66)
Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies (2011) (66)
The immunopathogenesis of multiple sclerosis and Guillain‐Barré syndrome (1996) (65)
Elevated cerebrospinal fluid and serum nitrate and nitrite levels in patients with central nervous system complications of HIV-1 infection: a correlation with blood-brain-barrier dysfunction (1998) (65)
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study (2014) (65)
Guthrie card methylomics identifies temporally stable epialleles that are present at birth in humans (2012) (65)
Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis (2011) (65)
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic (2020) (65)
Post-streptococcal autoimmune dystonia with isolated bilateral striatal necrosis. (2002) (64)
Streptococcal infection, Tourette syndrome, and OCD (2009) (63)
After the storm (2011) (63)
Epstein–Barr Virus and Multiple Sclerosis (2009) (63)
An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss (2008) (62)
Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis (2008) (62)
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study (2015) (62)
Vitamin D receptor ChIP-seq in primary CD4+ cells: relationship to serum 25-hydroxyvitamin D levels and autoimmune disease (2013) (62)
Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. (2012) (61)
Switching from natalizumab to fingolimod (2015) (61)
Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis (2013) (60)
Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: The DEFINE study (2014) (59)
The implications of immunogenicity for protein-based multiple sclerosis therapies (2008) (59)
e-Health and multiple sclerosis: An update (2018) (58)
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS) (2015) (57)
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study (2013) (57)
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects (2020) (56)
HLA-DRB1 and month of birth in multiple sclerosis (2009) (56)
Multiple sclerosis related fatigue (2005) (55)
Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta (2008) (55)
PREDICT‐PD: An online approach to prospectively identify risk indicators of Parkinson's disease (2017) (55)
Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy. (2015) (54)
Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis (2013) (54)
Assessing treatment response to interferon-β (2014) (54)
Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom (2020) (54)
No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation (2018) (54)
Early growth response gene-2 controls IL-17 expression and Th17 differentiation by negatively regulating Batf. (2013) (54)
Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring (2012) (53)
Choreic syndrome and coeliac disease: A hitherto unrecognised association (2004) (53)
Therapies for multiple sclerosis: considerations in the pediatric patient (2011) (53)
Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis (2011) (53)
Editors' welcome and a working definition for a multiple sclerosis cure. (2013) (52)
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. (2015) (52)
Epstein–Barr virus and multiple sclerosis: association or causation? (2013) (52)
Evidence for acute neurotoxicity after chemotherapy (2010) (52)
Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression (2013) (52)
Stiff person syndrome (2011) (52)
Pretreatment of Astrocytes with Interferon‐α/β Impairs Interferon‐γ Induction of Nitric Oxide Synthase (1997) (51)
Vitamin D receptor binding, chromatin states and association with multiple sclerosis (2012) (51)
Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. (2008) (51)
Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis (2004) (51)
Post‐Streptococcal autoimmune neuropsychiatric disease presenting as paroxysmal dystonic choreoathetosis (2002) (50)
Meta-Analysis of the Relationship between Multiple Sclerosis and Migraine (2012) (50)
Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis (2007) (50)
Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies (2017) (49)
Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids (2015) (49)
Quantification of neurodegeneration by measurement of brain-specific proteins (2003) (49)
Seasonal Distribution of Psychiatric Births in England (2012) (48)
The bradykinesia akinesia incoordination test (BRAIN TEST©), an objective and user‐friendly means to evaluate patients with Parkinsonism (2000) (48)
BMI and low vitamin D are causal factors for multiple sclerosis (2020) (48)
Antibasal ganglia antibodies and their relevance to movement disorders (2004) (47)
The McDonald Criteria for Multiple Sclerosis: time for clarification (2010) (47)
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy (2016) (47)
Bradykinesia-Akinesia Incoordination Test: Validating an Online Keyboard Test of Upper Limb Function (2013) (47)
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients (2016) (47)
Could antiretroviral drugs be effective in multiple sclerosis? A case report (2011) (47)
Depletion of CD52‐positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune‐tolerance promoting CD8 T‐cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis (2017) (46)
Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre (2003) (46)
Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy (2003) (46)
Cladribine: mechanisms and mysteries in multiple sclerosis (2018) (46)
Post-streptococcal opsoclonus-myoclonus syndrome associated with anti-neuroleukin antibodies (2006) (45)
Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. (2007) (45)
The effects of intrathecal rituximab on biomarkers in multiple sclerosis. (2016) (44)
Risk of fractures in patients with multiple sclerosis: A population-based cohort study (2012) (44)
Acute axonal damage predicts clinical outcome in patients with multiple sclerosis (2005) (44)
International consensus on quality standards for brain health-focused care in multiple sclerosis (2018) (44)
Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. (2016) (44)
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study (2013) (43)
Genetic Background Can Result in a Marked or Minimal Effect of Gene Knockout (GPR55 and CB2 Receptor) in Experimental Autoimmune Encephalomyelitis Models of Multiple Sclerosis (2013) (43)
Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets (2017) (43)
Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study (2018) (43)
Neutralising antibodies to interferon β in multiple sclerosis (2007) (42)
Prevalence of anti-basal ganglia antibodies in adult obsessive-compulsive disorder: cross-sectional study. (2012) (42)
Infusion-related hypersensitivity reactions during natalizumab treatment (2006) (42)
Oral contraceptive induced chorea: another condition associated with anti-basal ganglia antibodies (2004) (42)
Bone health and multiple sclerosis (2012) (42)
The clinical significance of an intrathecal monoclonal immunoglobulin band: a follow-up study. (2004) (42)
Translational Mini‐Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein–Barr virus entry to the central nervous system? (2012) (42)
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis (2020) (41)
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a (2018) (41)
Adult‐onset tic disorder, motor stereotypies, and behavioural disturbance associated with antibasal ganglia antibodies (2004) (41)
Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis. (2018) (41)
Considerations on discontinuing natalizumab for the treatment of multiple sclerosis (2010) (41)
Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice? (2005) (40)
Elevated salivary protein in Parkinson's disease and salivary DJ-1 as a potential marker of disease severity. (2015) (40)
The effect of gender in clinically isolated syndrome (CIS): a meta-analysis (2012) (40)
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial (2020) (40)
The importance of a multi-disciplinary perspective and patient activation programmes in MS management (2016) (40)
Increased urinary nitric oxide metabolites in patients with multiple sclerosis correlates with early and relapsing disease (1999) (40)
The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers (2005) (39)
Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19 (2020) (39)
Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis. (2014) (39)
Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study (2014) (38)
Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS) (2012) (38)
Hospital admissions for vitamin D related conditions and subsequent immune-mediated disease: record-linkage studies (2013) (37)
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study (2018) (37)
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis (2015) (37)
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study (2016) (37)
Parkinson’s disease determinants, prediction and gene–environment interactions in the UK Biobank (2020) (37)
Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis (2012) (36)
Cerebrospinal fluid tau concentrations in HIV infected patients with suspected neurological disease (2000) (36)
Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies. (2014) (36)
Bacterial vaccines for the treatment of multiple sclerosis and other autoimmune disorders. (2000) (36)
Neuroprotection in a Novel Mouse Model of Multiple Sclerosis (2013) (36)
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial (2017) (36)
Epstein–Barr virus, latitude and multiple sclerosis (2013) (36)
An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products. (2011) (36)
A brief history of NEDA. (2017) (35)
Cerebrospinal fluid levels of brain specific proteins in optic neuritis (2004) (35)
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (2018) (35)
Anti-basal ganglia antibodies in patients with atypical dystonia and tics (2004) (35)
Change practice now! Using atraumatic needles to prevent post lumbar puncture headache (2014) (35)
Protecting people with multiple sclerosis through vaccination (2020) (35)
Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis (2006) (34)
Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors (2013) (34)
Screening performance of abbreviated versions of the UPSIT smell test (2018) (34)
The diagnostic criteria for multiple sclerosis: From Charcot to McDonald. (2012) (33)
Testicular hypofunction and multiple sclerosis risk: A record‐linkage study (2014) (33)
Neural cell adhesion molecule — Description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders (2010) (33)
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies (2016) (33)
Viral pathophysiology of multiple sclerosis: A role for Epstein-Barr virus infection? (2010) (32)
Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders (2014) (32)
Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis (2014) (32)
Antineuronal antibody status and phenotype analysis in Tourette's syndrome (2007) (32)
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients (2016) (31)
Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment. (2017) (31)
Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1β (2017) (31)
Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon. (2012) (31)
Pediatric multiple sclerosis (2016) (31)
A practical review of the neuropathology and neuroimaging of multiple sclerosis (2016) (30)
Evaluating more naturalistic outcome measures (2015) (30)
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. (2007) (30)
Multiple sclerosis outpatient future groups: improving the quality of participant interaction and ideation tools within service improvement activities (2015) (29)
Neural cell adhesion molecules in brain plasticity and disease. (2013) (29)
Management of Secondary-Progressive Multiple Sclerosis (2004) (29)
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. (2012) (29)
Cerebrospinal fluid levels of nitric oxide metabolites predict response to methylprednisolone treatment in multiple sclerosis and optic neuritis (2002) (29)
Multiple Sclerosis and Demyelinating Diseases (2009) (28)
Strategies to treat and prevent the development of neutralizing anti-interferon-β antibodies (2003) (28)
The neurodegenerative prodrome in multiple sclerosis (2017) (28)
Vitamin D supplementation (2017) (28)
Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. (2012) (28)
Soluble adhesion molecules in Gilles de la Tourette's syndrome (2005) (28)
The clinical significance of an intrathecal monoclonal immunoglobulin band A follow-up study (2004) (27)
A dystonic syndrome associated with anti-basal ganglia antibodies (2004) (27)
Month of birth and thymic output. (2013) (27)
Systematic review and meta-analysis of the association between Epstein–Barr virus, multiple sclerosis and other risk factors (2020) (27)
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial (2018) (27)
Increased expression of colony‐stimulating factor‐1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss (2018) (27)
Epstein-Barr–negative MS: a true phenomenon? (2017) (27)
Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. (2014) (27)
Spread of T lymphocyte immune responses to myelin epitopes with duration of multiple sclerosis. (2005) (27)
Anti-basal ganglia antibodies and Tourette’s syndrome: a voxel-based morphometry and diffusion tensor imaging study in an adult population (2008) (26)
Multiple sclerosis in the Iranian immigrant population of BC, Canada: prevalence and risk factors (2014) (26)
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS (2016) (26)
Smouldering multiple sclerosis: the ‘real MS’ (2022) (26)
Cerebrospinal fluid nitrite/nitrate correlated with oxyhemoglobin and outcome in patients with subarachnoid hemorrhage (2004) (26)
Bone health in chronic neurological diseases: a focus on multiple sclerosis and parkinsonian syndromes (2013) (26)
Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement (2021) (26)
Serum and urine nitrate and nitrite are not reliable indicators of intrathecal nitric oxide production in acute brain injury (2003) (26)
Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis (2013) (26)
Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b (2003) (25)
Control of spasticity in a multiple sclerosis model using central nervous system‐excluded CB1 cannabinoid receptor agonists (2014) (25)
Multiple Sclerosis and Its Treatment (1999) (25)
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis (2017) (25)
Alemtuzumab depletion failure can occur in multiple sclerosis (2018) (25)
Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. (2017) (25)
Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier (2018) (25)
PANDAS: overview of the hypothesis. (2004) (24)
The Rebif® New Formulation Story (2007) (24)
Disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study (2014) (24)
Geography of hospital admissions for multiple sclerosis in England and comparison with the geography of hospital admissions for infectious mononucleosis: a descriptive study (2011) (24)
Validating a novel web-based method to capture disease progression outcomes in multiple sclerosis (2013) (24)
Vitamin D: a link between Epstein–Barr virus and multiple sclerosis development? (2011) (24)
A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Daclizumab HYP Monotherapy in Relapsing-Remitting Multiple Sclerosis: Primary Results of the SELECT Trial (S01.005) (2012) (24)
Late recurrences of Sydenham’s chorea are not associated with anti-basal ganglia antibodies (2004) (23)
Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis (2020) (23)
Vitamin D supplementation and antibodies against the Epstein-Barr virus in multiple sclerosis patients (2013) (23)
DNase hypersensitive sites and association with multiple sclerosis. (2014) (23)
Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE) (2015) (22)
Big conductance calcium‐activated potassium channel openers control spasticity without sedation (2017) (22)
Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. (2020) (22)
Chlamydophila pneumoniae infection of the central nervous system in patients with multiple sclerosis. (2004) (22)
Routine Cerebrospinal Fluid (CSF) Analysis (2008) (22)
Development of a sensitive ELISA for quantification of three- and four-repeat tau isoforms in tauopathies (2009) (21)
Long COVID or post COVID-19 syndrome (2021) (21)
Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography (2009) (21)
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study (2018) (21)
The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies (2020) (21)
Peripheral blood neurofilament light chain levels: the neurologist's C-reactive protein? (2018) (21)
A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. (2018) (21)
Are antibasal ganglia antibodies important, and clinically useful? (2007) (21)
Genomic Regions Associated with Multiple Sclerosis Are Active in B Cells (2012) (21)
Age-Associated Hyper-Methylated Regions in the Human Brain Overlap with Bivalent Chromatin Domains (2012) (21)
Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the ‘Spinal Tap’ (2010) (21)
Patients with clinically isolated syndromes suggestive of MS (2003) (20)
Science is 1% inspiration and 99% biomarkers (2017) (20)
Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis (2010) (20)
Inactive or moderately active human promoters are enriched for inter-individual epialleles (2013) (20)
Individualizing treatment goals and interventions for people with MS. (2012) (20)
Assessing interactions between HLA-DRB1*15 and infectious mononucleosis on the risk of multiple sclerosis (2013) (20)
Mifepristone or inhibition of 11β-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Δ(9)-tetrahydrocannabinol in mice (2003) (20)
Subtle motor disturbances in PREDICT-PD participants (2016) (19)
Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010. (2012) (19)
Prevalence of MS in Iranian Immigrants to British Columbia, Canada (2010) (19)
A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis (2020) (19)
Current and future role of interferon beta in the therapy of multiple sclerosis. (2010) (19)
Seroprevalence of herpes simplex virus type 2 in multiple sclerosis (2006) (19)
Development of resistance to biologic therapies with reference to IFN-β. (2012) (19)
Estimating the proportion of variation in susceptibility to multiple sclerosis captured by common SNPs (2012) (19)
Gender identity disorders and multiple sclerosis risk: A national record-linkage study (2016) (19)
Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial (2013) (18)
Inflammatory disorders of the central nervous system. (2003) (18)
Detection of 14-3-3 brain protein in cerebrospinal fluid of HIV infected patients (2000) (18)
Role of the HLA system in the association between multiple sclerosis and infectious mononucleosis. (2011) (18)
Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis (2021) (18)
No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study (2017) (18)
The role of infections in Behçet disease and neuro-Behçet syndrome. (2015) (18)
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial (2022) (18)
Personalized medicine in multiple sclerosis. (2017) (18)
Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study (S49.001) (2016) (18)
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis (2013) (18)
Urinary neopterin and nitric oxide metabolites as markers of interferon β-1a activity in primary progressive multiple sclerosis (2010) (18)
Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis. (1998) (18)
Cerebrospinal Fluid Biomarkers in Human Spinal Cord Injury from a Phase II Minocycline Trial. (2018) (18)
Tracing Sydenham’s chorea: historical documents from a British paediatric hospital (2005) (17)
Cerebrospinal fluid and urinary biomarkers in multiple sclerosis (2013) (17)
Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice (2011) (17)
Pretreatment of astrocytes with interferon-alpha/beta impairs interferon-gamma induction of nitric oxide synthase. (1997) (17)
Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a (2003) (17)
Dopamine reuptake transporter–single‐photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease (2018) (17)
To test or not to test (2008) (17)
Neuromyelitis optica and anti-aquaporin-4 antibodies: widening the clinical phenotype (2006) (17)
Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients. (2012) (16)
A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). (2017) (16)
Alcohol misuse disorders and multiple sclerosis risk. (2014) (16)
Transient Ischemic Attacks in Younger and Older Patients: A Comparative Study of 798 Patients in South Africa (1993) (16)
The Refinement of Genetic Predictors of Multiple Sclerosis (2014) (16)
Learning ability correlates with brain atrophy and disability progression in RRMS (2018) (16)
Change in pregnancy-associated multiple sclerosis relapse rates over time: a meta-analysis. (2020) (16)
Gene-environment interactions in Multiple Sclerosis: a UK Biobank study (2020) (16)
Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis (2017) (16)
Expert opinion on the use of cladribine tablets in clinical practice (2020) (16)
Natalizumab to fingolimod washout in patients at risk of PML (2014) (16)
Tumefactive neuro-Behçet disease (2004) (16)
Hypovitaminosis-D and EBV: no interdependence between two MS risk factors in a healthy young UK autumn cohort (2014) (16)
Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety (2020) (15)
Time- and Region-Specific Season of Birth Effects in Multiple Sclerosis in the United Kingdom. (2016) (15)
A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis (2020) (15)
Cerebrospinal fluid analysis. (2014) (15)
Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy–YES (2016) (15)
A service development study of the assessment and management of fracture risk in Parkinson’s disease (2014) (15)
Cytomegalovirus and multiple sclerosis risk (2013) (15)
Antineuronal antibodies in Parkinson's disease (2008) (15)
Vitamin D-dependent rickets, HLA-DRB1, and the risk of multiple sclerosis. (2010) (14)
Clinical results from AFFIRM: A randomized, double-blind, placebo-controlled, multicenter trial to determine the efficacy and safety of natalizumab in patients with relapsing multiple sclerosis (MS) (2005) (14)
Atraumatic needles for lumbar puncture: why haven't neurologists changed? (2015) (14)
Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine. (2018) (14)
Natalizumab significantly increases the cumulative probability of sustained improvement in physical disability (2008) (14)
Multiple Sclerosis, Lymphoma and Nasopharyngeal Carcinoma: The Central Role of Epstein-Barr Virus? (2009) (14)
Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk (2020) (14)
Psychiatric disorders in children with demyelinating diseases of the central nervous system (2018) (14)
A Risk Score for Predicting Multiple Sclerosis (2016) (14)
Comparative utility of disability progression measures in PPMS (2017) (13)
Progression in multiple sclerosis is associated with low endogenous NCAM (2013) (13)
Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis (2020) (13)
Immunological time-course of gadolinium-enhancing MRI lesions in patients with multiple sclerosis (1998) (13)
Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care (2019) (13)
Clinical Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study (P3.028) (2016) (13)
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis (2020) (13)
The new Bradykinesia Akinesia Incoordination (BRAIN) test: Preliminary data from an online test of upper limb movement (2012) (13)
Multiple sclerosis therapy and Epstein-Barr virus antibody titres. (2014) (13)
Enzymatic degradation of RNA causes widespread protein aggregation in cell and tissue lysates (2019) (13)
Epstein-Barr Virus and MS. (2011) (13)
The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis? (2015) (12)
Visibility and representation of women in multiple sclerosis research (2019) (12)
Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM (2016) (12)
BG-12 Increases the Proportion of Patients Free of Clinical and Radiologic Disease Activity in Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (PD5.005) (2012) (12)
Improving estimation of Parkinson’s disease risk—the enhanced PREDICT-PD algorithm (2020) (12)
Seroconversion following COVID-19 vaccination: Can we optimize protective response in CD20-treated individuals? (2021) (12)
Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis. (2017) (12)
The 'Field Hypothesis': rebound activity after stopping disease-modifying therapies. (2017) (12)
Severe chorea with positive anti-basal ganglia antibodies after herpesencephalitis (2006) (12)
Disease control and safety in relapsing remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32-week, rater- and patient-blind, randomized, parallel-group study (TOFINGO) (2013) (12)
Urinary markers of disease activity in multiple sclerosis (1998) (12)
CCSVI-A. A call to clinicans and scientists to vocalise in an Internet age. (2014) (12)
Sex ratio of infectious mononucleosis and possible relevance to multiple sclerosis (2013) (11)
Assessing fracture risk in people with MS: a service development study comparing three fracture risk scoring systems (2013) (11)
Urinary myelin basic protein‐like material as a correlate of the progression of multiple sclerosis (1996) (11)
Primary CNS Mantle Cell Lymphoma Associated with an Isolated CSF Monoclonal IgG Band (2003) (11)
Protein-Protein Interaction Analysis Highlights Additional Loci of Interest for Multiple Sclerosis (2012) (11)
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study (2021) (11)
Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept (2014) (11)
Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis (2012) (11)
Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (11)
Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. (2008) (11)
The BRadykinesia Akinesia INcoordination (BRAIN) tap test: capturing the sequence effect (2018) (11)
Pediatric multiple sclerosis Escalation and emerging treatments (10)
CSF analysis in suspected MS (2008) (10)
Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a (2001) (10)
The clinical significance of an intrathecal monoclonal immunoglobulin band (2003) (10)
Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (2012) (10)
Circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis (2000) (10)
ARPEGGIO: A randomized, placebo-controlled study to evaluate oral laquinimod in patients with primary progressive multiple sclerosis (PPMS) (P7.210) (2015) (10)
How long is the presymptomatic phase of multiple sclerosis? (2016) (10)
Glycolytic enzymes on neuronal membranes are candidate autoantigens in post-streptococcal neuropsychiatric disorders (2004) (10)
Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies. (2019) (10)
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry (2021) (10)
Promising emerging therapies for multiple sclerosis. (2011) (10)
Efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial (2016) (10)
TREATING MULTIPLE SCLEROSIS WITH CLADRIBINE (2016) (10)
Systematic review and meta-analysis of the association between Epstein-Barr virus, Multiple Sclerosis, and other risk factors (2019) (10)
Towards the incorporation of lumbar puncture into clinical trials for multiple sclerosis (2012) (10)
Antibasal ganglia antibodies and PANDAS (2005) (10)
Soluble adhesion molecules in acute disseminated encephalomyelitis. (2005) (10)
Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts. (2018) (10)
Integrating multiple oestrogen receptor alpha ChIP studies: overlap with disease susceptibility regions, DNase I hypersensitivity peaks and gene expression (2013) (10)
Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population. (2022) (10)
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings? (2018) (9)
Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis (2022) (9)
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. (2015) (9)
COVID-19 vaccines and multiple sclerosis disease-modifying therapies (2021) (9)
Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity. (2007) (9)
The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis (2017) (9)
Serum levels of 25-hydroxy vitamin D in normal Biozzi and C57BL/6 mice and during the course of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE) (2013) (9)
Neuropsychiatric-developmental model for the expression of tics, pervasive developmental disorder, and schizophreniform symptomatology associated with PANDAS (2009) (9)
Efficacy of Siponimod in Secondary Progressive Multiple Sclerosis: Results of the Phase 3 Study (CT.002) (2017) (9)
Haematological profiles in patients treated with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96 week, phase III, double-blind, placebo-controlled trial (2009) (9)
CSF neurofilament light chain testing as an aid to determine treatment strategies in MS (2020) (9)
COVID-19 vaccine response in people with multiple sclerosis. (2021) (9)
More to come: Humoral immune responses in MS (2011) (9)
Any evident MRI T2-lesion activity should guide change of therapy in multiple sclerosis - Yes (2015) (9)
IgG4-related disease: a rare but treatable cause of refractory intracranial hypertension (2015) (9)
The impact of social capital on patients with multiple sclerosis (2020) (9)
Urinary neopterin in idiopathic retinal vasculitis (2001) (9)
Autoaggressive immune-mediated movement disorders. (2005) (9)
Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment (2021) (9)
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years (2022) (9)
A Novel Functional Composite Endpoint to Characterize Disease Progression in Patients with Secondary Progressive Multiple Sclerosis (S12.006) (2019) (9)
Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practices. (2007) (9)
The potential of neurofilaments analysis using dry-blood and plasma spots (2020) (9)
Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis. (2019) (9)
Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT (2020) (8)
Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review (2022) (8)
Developing Biomarkers for MS. (2015) (8)
Extended dosing of monoclonal antibodies in multiple sclerosis (2021) (8)
Reduced immunogenicity with a new formulation of interferon-beta-1a (Rebif (R)): 24-week results of a phase IIIb study (2006) (8)
Advances in Clinical Neuroscience & Rehabilitation (2005) (8)
Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. (2017) (8)
Social capital: Implications for neurology (2018) (8)
Dementia risk in a diverse population: A single-region nested case-control study in the East End of London (2022) (8)
The effect of plasma exchange in accelerating clearance of natalizumab in patients with multiple sclerosis: results of the PLEX study (2007) (8)
Can we predict multiple sclerosis? (2009) (8)
[Copper deficiency as a treatable cause of poor balance]. (2010) (8)
Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis (2020) (8)
Patients with Active RRMS and an Inadequate Response to Prior Therapy Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS II Study (P3.022) (2016) (8)
No Evident Disease Activity—More Than a Risky Ambition? (2018) (8)
Should we rebrand multiple sclerosis a dementia? (2017) (8)
HEAVY METAL TOXICITY: LESSONS FROM A CASE OF SIMULTANEOUS OCCUPATIONAL EXPOSURE TO MANGANESE AND MERCURY (2013) (8)
Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study (2018) (8)
Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management (2018) (8)
Vitamin D receptor ChIP-seq in primary CD 4 + cells : relationship to serum 25-hydroxyvitamin D levels and autoimmune disease (2013) (8)
BG-12 (Dimethyl Fumarate) Treatment for Relapsing–Remitting Multiple Sclerosis (RRMS) Increases the Proportion of Patients Free of Measured Clinical and Neuroradiologic Disease Activity in the Phase 3 Studies (P07.106) (2013) (8)
Vitamin D and multiple sclerosis hospital admissions in Scotland. (2011) (8)
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial (2022) (8)
Impact of Siponimod on Cognition in Patients With Secondary Progressive Multiple Sclerosis: Results From Phase 3 EXPAND Study (S44.004) (2018) (7)
Antibodies to myelin oligodendrocyte glycoprotein as a biomarker in multiple sclerosis — are we there yet? (2007) (7)
Predicting disability worsening in relapsing and progressive multiple sclerosis (2021) (7)
Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. (2019) (7)
Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (7)
Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis (2005) (7)
Are there any body fluid markers of brain atrophy in multiple sclerosis? (1998) (7)
Obsessive-compulsive disorder and catatonia can be caused by antibasal ganglia antibodies. (2007) (7)
Disease modification in advanced MS: Focus on upper limb function (2017) (7)
GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains (2020) (7)
Results from the CLARITY Study: a Phase III, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Oral Cladribine in Relapsing-Remitting Multiple Sclerosis (RRMS) (2009) (7)
Updated Incidence of Natalizumab-associated Progressive Multifocal Leukoencephalopathy (PML) and Its Relationship with Natalizumab Exposure Over Time (2815) (2020) (7)
How to refer to people with disease in research outputs: The disconnection between academic practise and that preferred by people with multiple sclerosis. (2016) (7)
Comparison of two commercial ELISA systems for evaluating anti‐EBNA1 IgG titers (2013) (7)
Increased urinary excretion of nitric oxide metabolites in longitudinally monitored migraine patients (2006) (7)
Gene-Environment Interactions in Multiple Sclerosis (2021) (7)
Cerebrospinal fluid NCAM levels are modulated by disease‐modifying therapies (2019) (7)
World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application (2020) (7)
Mifepristone or inhibition of 11beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in mice. (2003) (7)
Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I (CARE-MS I): A Phase 3 Study in Relapsing-Remitting Treatment-Naïve Patients (S01.006) (2012) (7)
HLA‐DRB1*15, low infant sibling exposure, and multiple sclerosis gene–environment interaction (2009) (7)
Women on multiple sclerosis clinical trial steering committees (2018) (7)
Erratum: The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL (Journal of Neurology (2009) 256 (405-415) DOI: 10.1007/s00415-009-0093-1) (2009) (7)
Serum neurofilament-light concentration and real-world outcome in MS (2020) (7)
Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design (P3.2-091) (2019) (7)
Is EBV the cause of multiple sclerosis? (2022) (7)
Daclizumab high‐yield process reduced the evolution of new gadolinium‐enhancing lesions to T1 black holes in patients with relapsing−remitting multiple sclerosis (2016) (7)
Emerging therapies in multiple sclerosis (2005) (7)
Evaluation of no evidence of progression using composite outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial (2016) (6)
Web‐based assessment of Parkinson's prodromal markers identifies GBA variants (2015) (6)
Short commentary on ‘a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking’ (2010) (6)
Updated Safety Analysis of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis (2018) (6)
Effect of Alemtuzumab vs. Rebif(R) on Brain MRI Measurements: Results of CARE-MS I, a Phase 3 Study (S11.006) (2012) (6)
033 Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the oratorio study (ENCORE) (2018) (6)
No Evidence for Production of Intrathecal Immunoglobulin G against Acinetobacter or Pseudomonas in Multiple Sclerosis (2004) (6)
Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets in the clarity and clarity extension studies (2019) (6)
Vaccines and disease-modifying treatments. (2018) (6)
Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies (2021) (6)
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies (2021) (6)
Chronic lesion activity and disability progression in secondary progressive multiple sclerosis (2022) (6)
Copper deficiency as a treatable cause of poor balance (2010) (6)
Tackling comorbidity in multiple sclerosis. (2017) (6)
Is it multiple sclerosis or not? (2001) (6)
Immunological surrogate markers of disease activity in multiple sclerosis. (1999) (6)
Estimated and projected burden of multiple sclerosis attributable to smoking and childhood and adolescent high body-mass index: a comparative risk assessment. (2020) (6)
Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis : Analysis of Economic Data from the CLARITY Study. (2012) (6)
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies (2021) (6)
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials (2021) (6)
Can we afford not to prevent MS-related disability? (2017) (6)
Contribution of nitric oxide to exercise-induced hypotension in human sympathetic denervation (1999) (6)
Long-Term Efficacy of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis: 3 Year Results from the SELECTED Extension Study (P7.226) (2015) (5)
Results of the Phase 3 SPI2 Study of MD1003 (high dose Pharmaceutical grade Biotin) in Progressive MS (680) (2020) (5)
Durable Effect of Alemtuzumab on Disability Improvement in Patients With Relapsing-Remitting Multiple Sclerosis Who Relapsed on a Prior Therapy (P3.261) (2015) (5)
Effect of BG-12 on Brain Atrophy and Lesions Volume: MRI Results from the DEFINE Study during First and Second Year of Treatment (IN3-2.002) (2012) (5)
Durable efficacy of cladribine tablets in patients with multiple sclerosis: analysis of relapse rates and relapse-free patients in the CLARITY and CLARITY Extension studies (P6.353) (2017) (5)
Growth associated protein (GAP-43): Cloning and the development of a sensitive ELISA for neurological disorders (2014) (5)
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey (2021) (5)
Baseline Subgroup Characteristics of EXPAND: A Phase 3 Study of Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis (P3.084) (2016) (5)
ARPEGGIO: a placebo-controlled trial of oral laquinimod in primary progressive multiple sclerosis (S8.003) (2018) (5)
Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension (P5.379) (2017) (5)
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study (2020) (5)
Early onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (5)
Severe skin reactions associated with cladribine in people with multiple sclerosis. (2020) (5)
B cell therapy and the use of RNA-based COVID-19 vaccines (2021) (5)
Surviving stiff-person syndrome: a case report (2011) (5)
The role of antibody affinity for specific antigens in the differential diagnosis of inflammatory nervous system disorders (2006) (5)
Plasma exchange accelerates the decline of serum natalizumab concentration in patients with multiple sclerosis: Results of the natalizumab PLEX study (2008) (5)
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data (2021) (5)
Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis (P7.017) (2015) (5)
Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE (2017) (5)
Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study (2020) (5)
Reversal of the Pharmacodynamic Effects of Daclizumab HYP Following Treatment Washout: Results from the SELECTION Study (P05.188) (2013) (5)
Measuring treatment response to advance precision medicine for multiple sclerosis (2021) (5)
Detecting and predicting neutralization of alemtuzumab responses in MS (2020) (5)
Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not? (2020) (5)
Safety and Efficacy of Oral Cladribine in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the 96 Week Phase IIIb Extension Trial to the CLARITY Study (P07.119) (2013) (5)
Cerebrospinal fluid S-100b concentrations in patients with HIV infection. (1999) (5)
Uncoupling the Impact on Relapses and Disability Progression: Siponimod in Relapsing and Non-relapsing Patients With Secondary Progressive Multiple Sclerosis in the Phase III EXPAND Study (S8.005) (2018) (5)
The Potential for EBV Vaccines to Prevent Multiple Sclerosis (2022) (5)
Durable Effect of Alemtuzumab on Clinical Outcomes in Treatment-Naive Relapsing-Remitting Multiple Sclerosis Patients: Four-Year Follow-up of CARE-MS I (S4.007) (2015) (5)
Validation of an environmentally-friendly and affordable cardboard 9-hole peg test. (2017) (5)
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice (2021) (5)
Anti–basal ganglia antibodies are absent in patients with primary blepharospasm (2002) (5)
Probing the association between Multiple Sclerosis and Epstein Barr Virus from a therapeutic perspective. (2021) (5)
Gastrointestinal Tolerability Events in Relapsing–Remitting Multiple Sclerosis (RRMS) Patients Treated with Oral BG-12 (Dimethyl Fumarate) in DEFINE and CONFIRM (P01.164) (2013) (5)
Human swayback disease: expanding the spectrum of diseases associated with abnormal copper metabolism (2001) (4)
Reductions in MRI activity in relapsing-remitting multiple sclerosis achieved with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (4)
Lack of Serum Oligoclonal Antibody Responses to Chlamydophila pneumoniae in Multiple Sclerosis (2005) (4)
MSer - A new, neutral descriptor for someone with multiple sclerosis. (2014) (4)
A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe. (2015) (4)
Hidden Disabilities in Multiple Sclerosis The impact of Multiple Sclerosis on Patients and their Caregivers (2013) (4)
Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis. (2004) (4)
Long-Term Efficacy for Patients Receiving Cladribine Tablets in CLARITY/CLARITY Extension: Primary Results from 9–15 Years of Follow-Up in the CLASSIC-MS Study (2022) (4)
Is the incidence of multiple sclerosis really increasing? (2020) (4)
Inclusion criteria used in trials of people with progressive multiple sclerosis (2018) (4)
Clinical Efficacy of BG-12 (Dimethyl Fumarate) for Relapsing–Remitting Multiple Sclerosis (RRMS) According to Prior Therapy: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P07.128) (2013) (4)
A cell-based assay for the detection of neutralizing antibodies against alemtuzumab (2020) (4)
Long-term Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with RRMS: An Integrated Analysis of DEFINE, CONFIRM, and ENDORSE (P7.227) (2015) (4)
Plasma exchange augments leukocyte transmigration across an in vitro blood-brain barrier in natalizurnab-treated patients with multiple sclerosis (2008) (4)
Potential Conflicts of Interest (2014) (4)
Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis (2016) (4)
The CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY): design of a Phase III trial of oral cladribine in relapsing multiple sclerosis (2007) (4)
The Safety and Efficacy of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis in the SELECTION Extension Study: Primary Results (S01.001) (2013) (4)
Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis (2009) (4)
Incidence of natalizumab-associated progressive multifocal leucoencephalopathy and its relationship with the pattern of natalizumab exposure over time (2019) (4)
Effects of BG-12 on Magnetization Transfer Ratio in Whole Brain and Normal-Appearing Brain Tissue: Findings from the DEFINE Study (S11.004) (2012) (4)
Risks of psychiatric disorders in children and young adults with demyelinating diseases of the central nervous system: a national record-linkage study. (2016) (4)
Updated Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: Integrated Safety Analysis and Post-Approval Data (2020) (4)
Adaptation of the nitrate and Griess reaction methods for the measurement of serum nitrate plus nitrate levels - Reply (1998) (4)
The efficacy of natalizumab on magnetic resonance imaging (MRI) measures in patients with relapsing multiple sclerosis (MS): Results from the AFFIRM trial (2005) (4)
Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis. (2020) (4)
Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme (2019) (4)
Implications of Low-Titer MOG Antibodies. (2022) (4)
Importance of upper limb function in advanced multiple sclerosis (2016) (4)
Fingolimod Enhances Myelin Basic Protein Expression and Modulates Cytokine Production Following an Interferon-gamma Mediated Insult in the Whole Brain Aggregate Cell Culture System (2009) (4)
The effects of natalizumab on brain atrophy and cognitive function: results from the AFFIRM study (2006) (4)
Optimising MS disease-modifying therapies: antibodies in perspective (2004) (4)
Glatiramer acetate slows disability progression - results from a 6-year analysis of the UK Risk Sharing Scheme (2015) (4)
Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis (2010) (4)
Correction: Meta-Analysis of the Relationship between Multiple Sclerosis and Migraine (2013) (4)
Genome-wide association studies: will we ever predict susceptibility to multiple sclerosis through genetics? (2013) (4)
PO10-TU-39 Safety and tolerability of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (4)
Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study results (2016) (4)
Self-monitoring visual function via a smartphone application (2017) (4)
Anti-neuronal antibodies and movement disorders (2005) (4)
Predicting Multiple Sclerosis: Challenges and Opportunities (2022) (4)
Gender issues during the times of COVID‐19 pandemic (2021) (4)
OPL100 The effects of natalizumab on disability progression as measured by the Multiple Sclerosis Functional Composite (MSFC) and visual function in patients with relapsing MS (2005) (4)
Big pharma and social responsibility. (2020) (3)
Multiple Sclerosis and Vitamin D - Caviar or a Dog's Dinner? (2019) (3)
CSF GFAP (2010) (3)
The immunopathogenesis of multiple sclerosis. (1997) (3)
No Evidence of Disease Activity-3 Status Is Durable in Patients with Relapsing Multiple Sclerosis Receiving Cladribine Tablets: Clarity Extension (2018) (3)
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study (2022) (3)
Complexity of MS management in the current treatment era (2018) (3)
HERVs: have we been here before? (2012) (3)
Prevalence and demographics of multiple sclerosis-associated uveitis: a UK biobank study. (2020) (3)
The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions. (2022) (3)
MS-SMART trial design and recruitment status: a multi-arm phase IIB randomised double blind placebo-controlled clinical trial comparing the efficacy of three repositioned neuroprotective drugs in secondary progressive multiple sclerosis (2016) (3)
Towards a global view of multiple sclerosis genetics (2022) (3)
Testicular hypofunction and multiple sclerosis: Cause or consequence? Reply. (2014) (3)
Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course (2016) (3)
Treating multiple sclerosis with generic cladribine (2016) (3)
Cannabinoids and B cells: emerging targets for treating progressive multiple sclerosis (2011) (3)
Magnetic resonance imaging (MRI) outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets: results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial (2009) (3)
061 Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE) (2018) (3)
A Phase 3b/4 Long-Term Study of Alemtuzumab in Patients With Relapsing-Remitting Multiple Sclerosis: TOPAZ Study Design (P7.219) (2015) (3)
Gluten ataxia and post-streptococcal central nervous system syndromes: Emerging immune-mediated disorders of the central nervous system? (2005) (3)
Analysis of Clinical and Radiological Disease Activity-Free Status in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets, in the Double-Blind, 96-Week CLARITY Study (2010) (3)
Health-care disparities for people with multiple sclerosis (2020) (3)
How to start a blog (2017) (3)
Disease-free status achieved with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis (2009) (3)
Social determinants of health in multiple sclerosis (2022) (3)
Time and brain health both matter in multiple sclerosis. (2016) (3)
Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis (2021) (3)
Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients (2021) (3)
Quantitative demonstration of intrathecal synthesis of high affinity immunoglobulin G in herpes simplex encephalitis using affinity-mediated immunoblotting (2007) (3)
The REFLEX study: a missed opportunity? (2012) (3)
Air pollution and multiple sclerosis risk. (2021) (3)
Multiple sclerosis is one disease. (2022) (3)
Siponimod Reduces Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study (1130) (2020) (3)
Safety and Tolerability of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study (P3.095) (2016) (3)
Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis 1 / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking (2010) (3)
Exercise training in multiple sclerosis (2022) (3)
Sodium channel blockade with phenytoin has a neuroprotective effect on the ganglion cell complex after acute optic neuritis (2015) (3)
Immunogenicity of Rebif (R) New Formulation (interferon beta-1a) in patients with relapsing multiple sclerosis: results from a phase IIIb study (2008) (3)
Timecourse of Treatment Effects of BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis (2013) (3)
The anti-viral cytokine interferon-alpha is expressed in acute MS lesions and associated with the presence of Epstein-Barr virus infection (2009) (3)
Magnetic Resonance Imaging (MRI) Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets: Results from the 120-Week Phase IIIb Extension of the CLARITY Study (P2.114) (2016) (3)
Incidence of Autoimmunity in a Phase 3 Trial: Comparison of Alemtuzumab and Rebif(R) in Multiple Sclerosis I (CARE-MS I) (S41.006) (2012) (3)
Safety of cladribine tablets in the treatment of relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial (2009) (3)
TOWARDS AN ENDOPHENOTYPE IN MULTIPLE SCLEROSIS (2013) (3)
THE MS-SMART TRIAL IN SECONDARY PROGRESSIVE MS – CURRENT UPDATE (2016) (3)
Predictors of Conversion to Secondary Progressive Multiple Sclerosis in Patients With Relapsing–Remitting Multiple Sclerosis (P2.393) (2018) (3)
Cladribine effect on brain volume loss and its correlation with disability progression in patients with relapsing multiple sclerosis (2016) (2)
Risk factors and early non-motor features for Parkinson's disease: A systematic review and meta-analysis (2012) (2)
Anti-basal ganglia antibodies and Tourette syndrome: A phenotype analysis (2005) (2)
Phase 2 AFFINITY trial evaluates opicinumab in a targeted population of patients with relapsing multiple sclerosis: rationale, design and baseline characteristics (2018) (2)
PO134 Personalised dosing of cladribine to treat multiple sclerosis (2017) (2)
Sustained Improvement in Physical Disability with Natalizumab in Patients with Relapsing Multiple Sclerosis (2009) (2)
A guide to private prescribing (2015) (2)
Evaluation of activity, aggregation and NAB testing with generic interferon beta products: implications for treating multiple sclerosis (2008) (2)
Slower progression of Parkinson’s disease in patients treated with ropinirole compared with L-dopa: REAL-PET – a randomised controlled 18F-dopa PET study (2002) (2)
Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Relapsing Multiple Sclerosis in the OPERA I and OPERA II Trials (2018) (2)
Slowing of Disability Progression Based on 6-Month Confirmed EDSS in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets in the CLARITY Study: A Post-Hoc Subgroup Analysis (P3.058) (2016) (2)
The detection and significance of cerebrospinal fluid oligoclonal IgG (1996) (2)
Effect of BG-12 in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (P01.130) (2012) (2)
Durable Efficacy in RRMS Patients Receiving Two Annual Courses of Alemtuzumab and No Additional Treatment for 4 Years: Pooled Analysis of CARE-MS I and II (S51.005) (2016) (2)
Clinical Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis Patients with Highly Active Disease: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P7.228) (2015) (2)
PO129 Neda analysis by epoch in the opera studies of ocrelizumab (2017) (2)
PND63 Effects of BG-12 on Quality of Life in Relapsing–Remitting Multiple Sclerosis: Findings From the Phase 3 Define Study (2012) (2)
Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets (2022) (2)
Efficacy of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study (2011) (2)
Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary. (2022) (2)
FP36-WE-03 MRI outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (2)
MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Commentary (2021) (2)
Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. (2007) (2)
PND3 Relapses Requiring Intravenous Steroids and Multiple Sclerosis-Related Hospitalizations: Findings From the Phase 3 Define and Confirm Studies (2012) (2)
Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta (2018) (2)
THE BURDEN OF BLADDER DYSFUNCTION IN MULTIPLE SCLEROSIS: A MULTI-CENTRE AUDIT (2016) (2)
Optimising classification of Parkinson’s disease based on motor, olfactory, neuropsychiatric and sleep features (2021) (2)
Sustained Disability Improvement as Assessed by a Multicomponent Endpoint in Secondary Progressive Multiple Sclerosis (SPMS) Patients: A Post Hoc Analysis from ASCEND (P5.359) (2017) (2)
Removal of access to alemtuzumab for patients with aggressive multiple sclerosis (2013) (2)
Soluble adhesion molecules in Gilles de la Tourette's syndrome (vol 234, pg 79, 2005) (2006) (2)
Multiple sclerosis and migration revisited. (2019) (2)
Refining the Nosology of Antigen-Specific Diseases Within the Spectrum of Neuromyelitis Optica. (2018) (2)
Understanding drug resistance to biologic therapy Development of resistance to biologic therapies with reference to IFN-b (2012) (2)
Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis (2022) (2)
Infections in Phase 3 Study: Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis I (CARE-MS I) (S41.007) (2012) (2)
Multiple Sclerosis is a multifaceted disease. (2014) (2)
Do we have equipoise when it comes to how we treat active multiple sclerosis? (2019) (2)
Can rheumatologists stop causing demyelinating disease? (2021) (2)
Age-specific effects of childhood body mass index on multiple sclerosis risk (2022) (2)
Severe autoimmune chorea with positive antibasalganglia antibodies (ABGA) following herpesencephalitis: Treatment with plasmapheresis and corticosteroids (2005) (2)
Natalizumab increases the proportion of patients free of clinical or MRI disease activity in relapsing multiple sclerosis (2008) (2)
Assay selection affects John Cunningham virus serostatus classification in multiple sclerosis (2012) (2)
Predictors of an Opicinumab Treatment Effect and Identification of an Efficacy Subpopulation: A Post hoc Analysis of the SYNERGY Study (P3.408) (2018) (2)
The Yin and Yang of Inflammation in Multiple Sclerosis (2004) (2)
Improvement in Clinical Outcomes in Treatment-Naive Relapsing-Remitting Multiple Sclerosis Patients Who Switched From Subcutaneous Interferon Beta-1a to Alemtuzumab (P7.270) (2015) (2)
Maximising information on smell, quantitative motor impairment and probable REM-sleep behaviour disorder in the prediction of Parkinson’s disease (2020) (2)
Optical coherence tomography in secondary progressive multiple sclerosis: a baseline data report from the MS-SMART trial (2016) (2)
Survival: the ultimate long-term outcome in multiple sclerosis. (2019) (2)
SERUM NEUROFILAMENT LIGHT PROTEIN AND VISIN-LIKE PROTEIN-1 IN CONCUSSED PROFESSIONAL ICE HOCKEY PLAYERS (2014) (2)
An integrated analysis of relapses requiring intravenous steroid use and multiple sclerosis (MS)-related hospitalizations from the BG-12 (dimethyl fumarate) phase 3 define and confirm studies (2013) (2)
Proportion of Disease-Activity Free Patients with Relapsing-Remitting Multiple Sclerosis Following 1 Year of Treatment with Daclizumab High-Yield Process in the SELECT Study (P07.105) (2013) (2)
Systematic review and meta‐analysis of salivary protein concentration in Parkinson's disease (2015) (2)
Remote testing of vitamin D levels across the UK MS population—A case control study (2020) (2)
Treatment-Naive Patients with Active RRMS Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS I Study (S51.004) (2016) (2)
Overview of Differences and Similarities of Published Mixed Treatment Comparisons on Pharmaceutical Interventions for Multiple Sclerosis (2020) (2)
Is multiple sclerosis overdiagnosed? (2021) (2)
Long-Term Responders from the CARE-MS I Study: No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment (P3.054) (2016) (2)
Long-term Efficacy of Delayed-Release Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis According to Prior Therapy: Integrated Analysis of the DEFINE, CONFIRM, and ENDORSE Studies (P7.229) (2015) (2)
A comprehensive characterisation of the salivary proteome of patients with Parkinson's disease (2016) (2)
Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways? (2015) (2)
Editors' Welcome. (2017) (2)
Varicella-zoster virus encephalitis mimicking toxoplasmosis relapse (2015) (2)
Development and validation of luciferase reporter gene assay to measure anti-interferon beta neutralizing antibodies (2007) (2)
Tolerability Profile of Cladribine Tablets Therapy for Patients with Relapsing-Remitting Multiple Sclerosis: Factors Contributing to Treatment Completion in the Double-Blind, 96-Week, Placebo-Controlled CLARITY Study (2011) (2)
Relapse Outcomes with Alemtuzumab vs. Rebif® in Treatment-Naïve Relapsing-Remitting Multiple Sclerosis (CARE-MS I): Secondary and Tertiary Endpoints (PD5.004) (2012) (2)
Long-term Efficacy and Safety of Siponimod in Patients with SPMS: EXPAND Extension Analysis Up to 5 Years (4128) (2020) (2)
Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis. (2022) (2)
Theme 7 Pre-clinical therapeutic strategies (2019) (2)
Nitric oxide and exercise-induced hypotension in human sympathetic denervation (1997) (2)
Effects of natalizumab treatment on freedom from disease activity by baseline characteristics in AFFIRM (2013) (2)
Effect of Delayed-Release Dimethyl Fumarate on No Evident Disease Activity in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis Patients: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P7.247) (2015) (2)
Neutralising antibodies against interferon beta in multiple sclerosis (2004) (2)
MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression (2022) (2)
Why do you have to be lucky to get the MS treatment you deserve? (2016) (1)
Neuroprotection in a novel optic neuritis model (2011) (1)
Consistent efficacy of cladribine tablets across multiple sclerosis and patient characteristics, in the double-blind, 96-week CLARITY study (2010) (1)
Detection of antibodies against the N-methyl-d-aspartate receptor in a sub-group of patients diagnosed with Tourette's syndrome (2014) (1)
The incidence and clinical significance of antibodies to natalizumab over 2 years of treatment in patients with multiple sclerosis (2006) (1)
Should our treatment target in MS include the intrathecal plasma cell response? (2019) (1)
067 Efficacy of cladribine tablets in patients with highly active relapsing-remitting multiple sclerosis: analysis of pooled double-blind data from the clarity and onward studies (2018) (1)
Effects of BG-12 on Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (P07.102) (2012) (1)
Ageing and multiple sclerosis. (2020) (1)
EBV as the "gluten of MS" hypothesis provides a rationale for trialing antiviral therapies. (2022) (1)
Improvement in Disability With Alemtuzumab Is Associated With Quality of Life Improvement Over 3 Years in Patients Who Relapsed on Prior Therapy (P3.260) (2015) (1)
Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS) (2012) (1)
DESIGNING AN INFORMATION RESOURCE TO EXPLAIN DIAGNOSTIC LUMBAR PUNCTURE AND PROMOTE BEST PRACTICE (2015) (1)
Long-Term Safety of Daclizumab HYP in Patients with Relapsing-Remitting Multiple Sclerosis: 3-4 Year Results from the SELECTED Extension Study (P7.225) (2015) (1)
Remyelination trial failures: Repercussions of ignoring neurorehabilitation and exercise in repair. (2022) (1)
No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment: Long-Term Responders from the CARE-MS II Study (P3.059) (2016) (1)
A study on the possible association of dysfunctional uterine bleeding with bacterial vaginosis , mycoplasma , ureaplasma , and Gardnerella vaginalis (1)
Predicting multiple sclerosis: a large international multicentre study (2015) (1)
Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. (2021) (1)
Longer-term Safety with Siponimod Treatment in Multiple Sclerosis: Pooled Analysis of Data from the Bold and Expand Trials and their Extensions (2018) (1)
Pain in patients with multiple sclerosis: Effects of natalizumab (2008) (1)
Primary Progressive Multiple Sclerosis (2012) (1)
FP36-WE-02 Clinical outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (1)
Improvement in Clinical Outcomes Following Switch From Subcutaneous Interferon Beta-1a to Alemtuzumab: CARE-MS II Extension Study (P7.278) (2015) (1)
BG-12 effects on quality of life in relapsing–/INS;remitting ms patients: Integrated analysis of the Phase 3 DEFINE and CONFIRM studies (2013) (1)
127 Attitudes towards end of life issues among people with MS: a 360 survey (2012) (1)
Efficacy of Delayed-Release Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis (RRMS) in “Non-Responders” to Prior Treatment with Interferon Beta (P3.239) (2015) (1)
Baseline Characteristics of Pediatric Patients with Multiple Sclerosis Enrolled in the PARADIGMS Study: A Randomized, Double-Blind Study of Fingolimod versus Interferon-β-1a (P1.347) (2017) (1)
2 Epstein–Barr Virus and Multiple Sclerosis Wrong Place, Wrong Time? (2011) (1)
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey (Preprint) (2021) (1)
Natalizumab improves health-related quality of life in patients with relapsing multiple sclerosis (2006) (1)
Can serum glial fibrillary acidic protein (GFAP) solve the longstanding problem of diagnosis and monitoring progressive multiple sclerosis. (2021) (1)
What do we do with positive neutralising antibody tests in subjects with MS (2009) (1)
Measuring anti-interferon beta neutralising antibodies - A novel cell-based assay (2006) (1)
Is multiple sclerosis a risk factor for infections? (2020) (1)
Evaluation of the Treatment Effect of Cladribine Tablets in the Cohort of Patients Who Had Failed Prior Treatment with Injectable Disease-Modifying Drugs: The CLARITY Relapsing-Remitting Multiple Sclerosis Study (2011) (1)
Alcohol-use disorders and multiple sclerosis risk: a national record-linkage study (2014) (1)
Effect of Delayed-Release Dimethyl Fumarate on Freedom from Measured Clinical and Neuroradiological Disease Activity in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: An Integrated Analysis of DEFINE and CONFIRM (P3.159) (2014) (1)
Natalizumab improves disability on the Multiple Sclerosis Functional Composite in a randomised, double-blind, placebo-controlled study of patients with relapsing multiple sclerosis (2009) (1)
Nitric Oxide and Headache: Related, But How? (2003) (1)
Chorea gravidarum: Another condition associated with Sydenham's chorea and antibasal ganglia antibodies (2004) (1)
Neurofilament light chain A prognostic biomarker in amyotrophic lateral sclerosis (1)
Quality of life improvements in patients with active relapsing-remitting multiple sclerosis are not impacted by acute infections after receiving alemtuzumab in CARE-MS II (2015) (1)
Relapses Requiring Intravenous Steroid Use and Multiple Sclerosis (MS)-Related Hospitalizations: An Integrated Analysis of the BG-12 (Dimethyl Fumarate) Phase 3 Studies (P07.121) (2013) (1)
Is the 'MS establishment' biased; the case for addressing gender inequality in the field of MS? (2019) (1)
ECTRIMS 2012: Treatment highlights. (2013) (1)
Evaluation of remote assessments for multiple sclerosis in an in-home setting. (2021) (1)
Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis (2019) (1)
Lesson of the month (2) (2009) (1)
Daclizumab HYP Reduces the Evolution of New Gadolinium-Enhancing Lesions to T1-Black Holes: Results from the SELECT Study (P07.094) (2013) (1)
Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals? (2022) (1)
THINK OUTSIDE THE BOX, COLLAPSE THE BOX, AND TAKE A SHARP KNIFE TO IT! (2013) (1)
Raised prevalence of herpes simplex type-2 antibody in multiple sclerosis (2006) (1)
Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis (2021) (1)
Vitamin D deficiency--do we follow our own advice? (2011) (1)
Re-emergence of encephalitis lethargica-like syndrome: Evidence of CNS autoimmunity (2002) (1)
COVID-19 vaccine-readiness for ocrelizumab and other anti-CD20-depleting therapies in multiple sclerosis and other autoimmune diseases (2020) (1)
The effects of natalizumab on disability progression in the AFFIRM study: correlation between changes in Multiple Sclerosis Functional Composite and Expanded Disability Status Scale scores (2005) (1)
How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies? (2022) (1)
GBA1 and LRRK2 mutations in higher and lower risk subjects from the PREDICT-PD project (2014) (1)
Safety and tolerability of Rebif((R)) New Formulation (interferon beta-1a) in patients with relapsing multiple sclerosis: results from a phase IIIb study (2008) (1)
Long-term Follow-up of the Effect of Delayed-Release Dimethyl Fumarate on No Evidence of Disease Activity in Patients with Multiple Sclerosis (P7.280) (2015) (1)
Effect of Delayed-Release Dimethyl Fumarate on Health-Related Quality of Life in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients According to Prior Therapy: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P3.162) (2014) (1)
EBV and multiple sclerosis: Setting the research agenda. (2022) (1)
039 Rates of lymphopenia in years 1–4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets (2018) (1)
064 Expert consensus on standards for multiple sclerosis care: results from a modified delphi process (2018) (1)
THE USE OF MAGNETIC RESONANCE IMAGING (MRI) IN THE MANAGEMENT OF MULTIPLE SCLEROSIS IN THE UK (2014) (1)
Exploring correlations between changes in lymphocyte counts and clinical/magnetic resonance imaging outcomes in cladribine-treated patients with relapsing-remitting multiple sclerosis: analyses from the double-blind, 96-week CLARITY study (2011) (1)
OPTIMISE - A Web-Based Solution for Recording and Analyzing Longitudinal Multiple Sclerosis Data (P2.116) (2016) (1)
Complete clinical and magnetic resonance imaging response with natalizumab in multiple sclerosis (2008) (1)
A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis (2012) (1)
Editors' Welcome. (2017) (1)
Initial cross-sectional MR spectroscopy analysis of a cohort of secondary progressive MS patients enrolled in the MS-SMART trial (2016) (1)
Post‐streptococcal autoimmune dystonia with isolated bilateral striatal necrosis (2002) (1)
Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results (2016) (1)
Cerebrospinal fluid nitrite/nitrate predicts poor outcome in patients with subarachnoid hemorrhage (SAH) (2003) (1)
Cladribine tablets in patients who had failed prior treatment with injectable disease-modifying drugs for relapsing-remitting multiple sclerosis: evaluation of treatment effect in the CLARITY study (2011) (1)
Distinguishing physiological versus pathological serum NfL levels in multiple sclerosis will require serial measurements. (2020) (1)
Digesting science: Developing educational activities about multiple sclerosis, prevention and treatment to increase the confidence of affected families. (2020) (1)
Effects of natalizumab treatment on sustained improvement in physical disability and quality of life in patients with relapsing multiple sclerosis (2009) (1)
Reduction of risk of secondary progressive multiple sclerosis within two years of treatment with cladribine tablets: An analysis of the clarity study (2019) (1)
Multiple sclerosis and migraine: Links, management and implications. (2022) (1)
IIIb study in patients with relapsing multiple sclerosis : 96-week results-1 a ( Rebif ® New Formulation ) in a Phase β Safety and immunogenicity of a new formulation of interferon (2009) (1)
Selective targeting of neuroprotection to MS lesions: sodium channel blockers in experimental autoimmune encephalomyelitis (2011) (1)
The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis (2022) (1)
Efficacy of Delayed-Release Dimethyl Fumarate for RRMS in Prior Interferon Users in the DEFINE and CONFIRM Studies (P7.231) (2015) (1)
Natalizumab increases the proportion of disease-free patients in relapsing multiple sclerosis (2008) (1)
Epstein Barr virus shedding in multiple sclerosis : similar frequencies of EBV in saliva across separate patient (2018) (1)
Timing is everything in the treatment of multiple sclerosis (2015) (1)
Reconstitution of circulating lymphocyte subsets after treatment with cladribine tablets in the 96-week CLARITY study in relapsing-remitting multiple sclerosis (2010) (1)
ONSET OF MULTIPLE SCLEROSIS IS PREVENTABLE - TIME TO ACT NOW! (2022) (1)
National survey of UK medical students on the perception of neurology (2014) (1)
Cerebrospinal fluid neurofilament heavy chain levels in acute optic neuritis and multiple sclerosis patients treated with oral high-dose methylpredinolone (2004) (1)
Author Correction: The potential of neurofilaments analysis using dry-blood and plasma spots (2020) (1)
Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment for Multiple Sclerosis (2022) (1)
Antibodies to neurofilament light as potential biomarkers in multiple sclerosis (2021) (1)
Gavin Giovannoni on why time matters in multiple sclerosis. (2016) (1)
Efficacy of Cladribine Tablets 3.5 mg/kg in High Disease Activity (HDA) Subgroups of Patients with Relapsing Multiple Sclerosis (RMS) in the CLARITY Study (P6.360) (2017) (1)
Rapid and sustained efficacy with cladribine tablet treatment in relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial (2009) (1)
Lymphopenia Rates in Clarity/clarity Extension Are Unrelated to Disease Activity at Baseline (2018) (1)
Diagnosis of multiple sclerosis: Progress or confusion? (2022) (1)
Optical coherence tomography (OCT), visual function and MRI measures in acute optic neuritis: baseline data from a clinical trial (2013) (0)
Urinary neopterin is a sensitive marker of longitudinal interferon beta-1a treatment in primary progressive multiple sclerosis patients (2004) (0)
Title : Regarding : Nicotinic acetylcholine receptors α 7 and α 9 modifies tobacco smoke risk for multiple sclerosis (2021) (0)
The effects of natalizumab monotherapy on multiple measures of disability progression in MS patients (2006) (0)
Multiple sclerosis and the optometrist (2000) (0)
Making science digestible: the development of educational activities for children with a parent with MS, and the need to better engage families (2018) (0)
Big conductance calcium-activated potassium channel activation is a novel way to control spasticity without sedation (2016) (0)
ALEMTUZUMAB IMPROVES 3-YEAR QUALITY OF LIFE IN CARE-MS II (2015) (0)
Cladribine for the Effective Control of Multiple Sclerosis via Memory B Cell Depletion (S52.007) (2018) (0)
Myopia in late adolescence and subsequent multiple sclerosis among men. (2023) (0)
Editor's Welcome. (2012) (0)
HERVs: have we been here before? (2013) (0)
Magnetic resonance imaging results from AFFIRM: a randomised controlled trial of natalizumab in patients with relapsing multiple sclerosis (2005) (0)
What is required for a biomarker to become a good surrogate outcome (2005) (0)
Overall Response Score: A Novel Disability Endpoint That Allows for the Integrated Assessment of Improvement and Worsening over Time in Patients with MS (P4.380) (2018) (0)
PO109 Is there an ethnicity bias of access to multiple services in the nhs? – the barts health experience (2017) (0)
What are T-cells telling us about how EBV causes MS? (2022) (0)
International Consensus on Smoldering Disease in Multiple Sclerosis using the Delphi Method (P11-3.013) (2023) (0)
Editors' Welcome. (2016) (0)
Time Matters in Multiple Sclerosis - International Consensus Recommendations on Diagnosis, Management and Treatment Access (P1.340) (2016) (0)
Neural cell adhesion molecule as a biomarker of neuro-regeneration in experimental autoimmune encephalomyelitis (2008) (0)
Three suggestions to decrease the financial burden of MS treatments. (2019) (0)
PO138 High disease activity in relapsing multiple sclerosis (rms) (2017) (0)
CLASSIFICATION OF JC VIRUS SEROSTATUS DEPENDS UPON ASSAY SELECTION: A COMPARISON OF BIOGEN AND HPA ASSAYS (2012) (0)
Editors' welcome. (2012) (0)
Precision Medicine in the MS: Current state and new biological tools (2019) (0)
Progression Independent of Relapse Activity (PIRA) in Patients with Relapsing Multiple Sclerosis (2019) (0)
Durabilité du statut NEDA-3 (No Evidence of Disease Activity) chez les patients atteints d’une forme récurrente de sclérose en plaques (SEP-R) recevant Cladribine Comprimés 3,5 mg/kg (CT3,5) : CLARITY Extension (2019) (0)
Delayed-release Dimethyl Fumarate demonstrates sustained efficacy over nine years in newly diagnosed patients with relapsing-remitting multiple Sclerosis (2019) (0)
Integrating multiple oestrogen receptor alpha ChIP studies: overlap with disease susceptibility regions, DNase I hypersensitivity peaks and gene expression (2013) (0)
Regarding: Nicotinic acetylcholine receptors α7 and α9 modify tobacco smoke risk for multiple sclerosis (2020) (0)
Functional effects of anti-neuronal antibodies from patients with Tourette's syndrome and disorders associated with streptococcal infection (2014) (0)
Demyelination and axonal loss in rat brain aggregate cultures enriched with macrophages following inteferon-gamma induced demyelination (2007) (0)
Editors' Welcome. (2016) (0)
Diagnosing and caring for MS in Haiti. (2018) (0)
Review article The role of antibody affinity for specific antigens in the differential diagnosis of inflammatory nervous system disorders (2006) (0)
CLINICAL EXPERIENCE OF CLADRIBINE USE IN A LARGE UK COHORT – SIDE EFFECT PROFILES, INCLUDING LYMPHOCYTOPAENIA AND REAL-WORLD IN MS (0)
Becoming blind in one eye (2016) (0)
Acquired copper deficiency mimicking sub acute combined degeneration of the spinal cord (2005) (0)
OCULAR FLUTTER-OPSOCLONUS-MYOCLONUS SYNDROME IN AN ADULT NEUROLOGICAL PRACTICE: AETIOLOGY AND OUTCOME (2009) (0)
WED 185 Clarity: mri outcomes in high disease activity relapsing ms (2018) (0)
CAN WE RELIABLY USE MRI TO MONITOR TREATMENT RESPONSE IN PATIENTS ON INTERFERON β: A SYSTEMATIC REVIEW AND META-ANALYSIS (2012) (0)
Editors' Welcome. (2015) (0)
Clinical governance implications of using mitoxantrone within neurology - lessons from a specialist centre (2004) (0)
118 The new Bradykinesia Akinesia Incoordination (BRAIN) test: an online test of upper limb movement (2012) (0)
Identification of Epstein-Barr Virus Associated Epigenetic Changes and Association with Multiple Sclerosis (2011) (0)
Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, With Particular Reference to Liver Safety (P7-3.010) (2023) (0)
Cancer risk and mortality in multiple sclerosis: The need for vigilance. (2023) (0)
Raised serum nitric oxide metabolites are related to disease activity in patients with multiple sclerosis: 1-year follow-up study (2005) (0)
Is cognitive impairment in multiple sclerosis reversible? (2018) (0)
Soluble adhesion molecules in Tourette syndrome (2004) (0)
Impairment of astrocytic nitric oxide function by interferon-alpha/beta (1997) (0)
ECTRIMS 2016 Committees (2016) (0)
Editors' welcome. (2014) (0)
152 AttackMS natalizumab for the treatment of people with inflammatory demyeli- nation suggestive of multiple sclerosis (2022) (0)
Unpaired oligoclonal bands persist in the cerebrospinal fluid of patients with multiple sclerosis following treatment with alemtuzumab (2008) (0)
Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Delayed-Release Dimethyl Fumarate: A Three-Year Interim Analysis of ENDORSE (P7.236) (2015) (0)
Safety and immunogenicity of interferon beta-1a (Rebif (R) New Formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 48-week results (2007) (0)
A Multivariate Risk Calculator for Multiple Sclerosis and Study of an Endophenotype in Siblings of People with Multiple Sclerosis (S34.002) (2014) (0)
Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis Using a Composite Measure of Disability: Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P2.144) (2016) (0)
Safety and Efficacy of Long-Term Treatment With Daclizumab Beta: 6-Year Results From the SELECTED Extension Study (P6.390) (2018) (0)
Raised urinary neopterin excretion is associated with a better clinical outcome in PP-MS patients treated with interferon beta-1a (2006) (0)
WITHDRAWN: A narrative to explain worsening secondary progressive multiple sclerosis (2019) (0)
Is it time to consider rationalising IFN-β treatment in individuals with multiple sclerosis? (2004) (0)
"Is this new medicine going to help me walk again?" (2020) (0)
DEVELOPING IMPROVED GUIDELINES TO INTERPRET ANTI-IFN NEUTRALISING ANTIBODY TITRES: CORRELATION OF IN VIVO MARKERS OF IFNB; BIOACTIVITY (MXA) WITH LUCIFERASE REPORTER GENE NAB TITRES (2009) (0)
PO137 Efficacy of cladribine tablets in high disease activity rms (2017) (0)
Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool (2022) (0)
Different TRADD expression discriminates between multiple sclerosis disease subtypes (2006) (0)
RECRUITMENT IN MULTIPLE SCLEROSIS TRIALS: THE MS-SMART EXPERIENCE (2016) (0)
Tolerability profile of cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis: factors contributing to treatment completion overall and in patients with high disease activity in the 96-week CLARITY study (2011) (0)
Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis (S33.007) (2017) (0)
THUR 192 Yearly lymphopenia rates in cladribine tablets-treated rms patients (2018) (0)
THE BRADYKINESIA–AKINESIA INCOORDINATION TEST: A SIMPLE OBJECTIVE TEST IN MULTIPLE SCLEROSIS (2013) (0)
Editors' Welcome. (2017) (0)
GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains (2020) (0)
Phenytoin for neuroprotection in acute optic neuritis: a randomised, placebo-controlled, phase 2 trial (2016) (0)
Objective decrement in Parkinson's disease - A new parameter for the BRAIN tap test (2016) (0)
Optimising classification of Parkinson’s disease based on motor, olfactory, neuropsychiatric and sleep features (2021) (0)
The relationship between disease severity and health-related quality of life in patients with relapsing multiple sclerosis (2006) (0)
[Differentiated carcinoma of the thyroid]. (1984) (0)
Subject Index Vol. 32, 2009 (2009) (0)
Reduced cerebrospinal fluid neural cell adhesion molecule (NCam) in neurological disorders, a reflection of the capacity for neuronal regeneration (2008) (0)
Cladribine to Treat Relapsing Forms of Multiple Sclerosis (2017) (0)
IMMUNOCOMPETENT PML—AN IMMUNOLOGICAL SCOTOMA? (2014) (0)
PREDICT-PD study: Online screening algorithm identifying Parkinson's disease risk (2013) (0)
Prognostic Factors Associated with Axonal Loss after Optic Neuritis (P4.175) (2016) (0)
Grassroot efforts towards diversity in MS care and research: Win-win for patients and science. (2019) (0)
Simvastatin in patients with progressive multiple sclerosis (2014) (0)
Unaltered frequency and functionality of CD56bright and CD56dim natural killer cells in untreated relapsing–remitting multiple sclerosis patients (2014) (0)
Author Correction: The potential of neurofilaments analysis using dry-blood and plasma spots (2020) (0)
Patients with RRMS Who Had an Inadequate Response to a Prior Therapy Demonstrated Durable Improvement in EDSS Functional Systems Scores Over 5 Years with Alemtuzumab (P6.186) (2016) (0)
A SERVICE DEVELOPMENT AUDIT OF FAMPRIDINE USE IN MS (2013) (0)
B Cells and EBV Infection in People with MS (2009) (0)
Are the high-costs of MS disease-modifying therapies justified? (2018) (0)
Dystonia in adolescents and adults associated with anti-basal ganglia antibodies (2002) (0)
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis. (2023) (0)
Intrathecal antibodies to neurofilament light (NF-L) correlate with MRI markers of axonal loss (2002) (0)
The future of microbiome research in neuroinflammatory disorders. (2020) (0)
The immunogenicity of natalizumab in patients with multiple sclerosis: Results from the AFFIRM study (2007) (0)
VSN16R – A NOVEL TREATMENT FOR SPASTICITY IN EXPERIMENTAL MULTIPLE SCLEROSIS (2016) (0)
The potential of neurofilaments analysis using dry-blood and plasma spots (2020) (0)
Editors' Welcome: Pregnancy and progressive multifocal leukoencephalopathy. (2018) (0)
HLA-DRB 1 * 15 , Low Infant Sibling Exposure , and Multiple Sclerosis Gene – Environment Interaction (2010) (0)
The new bradykinesia akinesia incoordination (BRAIN) test: People with Parkinson's disease versus healthy controls (2012) (0)
Polygenic risk score prediction of multiple sclerosis in individuals of South Asian ancestry (2023) (0)
Personalised dosing of cladribine for people with multiple sclerosis (P3.400) (2018) (0)
Impact of sustained disability progression and relapses on visual outcomes in the AFFIRM trial (2007) (0)
Are we ready for CD19-targeted CAR T-cell therapies in MS? (2023) (0)
It is time to move to alternative clinical trial designs: Reconsidering the holy grail of trial methodology. (2021) (0)
131 Do siblings of people with multiple sclerosis (MS) have markers of MS risk? (2012) (0)
“Double whammy” neuropathy: a 37-year-old woman with burning and weakness in both legs (2006) (0)
VP167 Comparison Of Methodology In Mixed Treatment Comparisons Of Treatments For Multiple Sclerosis (2017) (0)
Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis (2022) (0)
Young Scientific Investigators - ECTRIMS 2013 (2013) (0)
Effectiveness of Lymphocyte-based Re-treatment Criteria in Minimizing the Incidence of Severe Sustained Lymphopenia during Treatment with Cladribine Tablets 3.5mg/kg (P5.370) (2018) (0)
Editors' Welcome. (2016) (0)
Poststreptococcal Movement Disorders (2008) (0)
Amyloidoma mimicking multiple sclerosis (2021) (0)
043 Efficacy of siponimod in secondary progressive multiple sclerosis with active disease: EXPAND study subgroup analysis (2022) (0)
Editors' Welcome. (2018) (0)
021 Determinants of natalizumab-associated PML outcomes (2022) (0)
Recent developments in oral medications for the treatment of multiple sclerosis (2010) (0)
A sensitive ELISA method for the detection of human neural cell adhesion molecule (NCam) in cerebrospinal fluid (2007) (0)
Immune tolerance strategies to reverse the development of neutralising anti-interferon-beta antibodies (2006) (0)
Epstein-Barr virus seroprevalence in multiple sclerosis patients: a systematic review and meta-analysis (2012) (0)
The association between sunlight hours and month of birth in multiple sclerosis patients across UK regions (2012) (0)
High efficacy treatment is not enough in MS: Socioeconomic factors are key to improving outcomes. (2022) (0)
018 Disease control beyond NEDA: the value of non-clinical measures to determine treatment response to natalizumab (2022) (0)
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. (2023) (0)
Anti-neuronal glycolitic enzymes antibodies: a study on primary neuronal striatal cultures (2006) (0)
The effect of natalizumab on brain atrophy in patients with relapsing multiple sclerosis: 2-year results from the AFFIRM study (2005) (0)
022 Updated safety of cladribine tablets in multiple sclerosis patients: integrated safety analysis and post-approval data (2022) (0)
[PANDAS: overview of the hypothesis]. (2004) (0)
INCREASED SERUM IL-8 LEVELS IN BEHCET DISEASE THAN NEUROBEHCET SYNDROME (2011) (0)
Discrepant fi ndings in immune responses to JC virus in patients receiving natalizumab (2010) (0)
Bone health in multiple sclerosis: should we be doing more? (2013) (0)
Defining High Disease Activity (HDA) in Patients with Relapsing Multiple Sclerosis (RMS) Receiving Placebo in the CLARITY Study (P6.351) (2017) (0)
Expression of ferritin and S-100B in relation to nitric oxide metabolites in the cerebrospinal fluid of relapsing multiple sclerosis patients (2006) (0)
The design of the CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY) (2006) (0)
Antiretroviral treatment in patient with secondary progressive multiple sclerosis — /INS;Impact on disease progression and safety (2013) (0)
Premonitory urges in tourette syndrome: A voxel based morphometry and diffusion tensor imaging MRI study (2008) (0)
DACLIZUMAB HYP IN MULTIPLE SCLEROSIS: 3-YEAR RESULTS FROM SELECTED (2016) (0)
THE MS-SMART TRIAL IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS: A MULTI-ARM, MULTI-CENTRE TRIAL OF NEUROPROTECTION (2015) (0)
Dare we mention the C-word? (2020) (0)
WED 182 Cladribine tablets effects on lymphocytes in ms patients (2018) (0)
Assessment of anti-beta-interferon neutralising antibodies status and disease severity in a cohort of multiple sclerosis patients (2007) (0)
Neutralising antibodies to interferon beta - Reply (2003) (0)
148 The effect of natalizumab and interferon-β on urinary free light chains and anti-EBV nuclear antigen-1 antibodies in relapsing remitting multiple sclerosis (2012) (0)
PO136 Durable efficacy of cladribine tablets: clarity+extension (2017) (0)
146 MRI activity versus relapses as markers of SPMS disease activity: real world and pivotal trials (2022) (0)
158 Why can't I win any more? (2012) (0)
Letter to the editor (2004) (0)
A comparison of the immunology and histopathology in post mortem multiple sclerosis brain (2005) (0)
Evaluation of anti-interferon beta antibodies in subjects with multiple sclerosis attending the national hospital for neurology and neurosurgery, London (2007) (0)
First Oral Short-course Treatment for Adults with Highly Active Relapsing Multiple Sclerosis Now Approved in Europe (2017) (0)
REAL WORLD EXPERIENCE OF FINGOLIMOD IN MULTIPLE SCLEROSIS: THE LONDON AUDIT (2016) (0)
Longer-Term Follow-Up of the Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: Integrated Analysis of DEFINE, CONFIRM, and ENDORSE (P3.033) (2016) (0)
136 NOVA primary results randomised controlled study of natalizumab Q6W versus continued Q4W treatment for MS (2022) (0)
Cerebrospinal fluid markers of tissue destruction and repair in multiple sclerosis (2001) (0)
Increase of uric acid and purine compounds in serum of multiple sclerosis patients (2009) (0)
biobanking A consensus protocol for the standardization of cerebrospinal fluid collection and (2009) (0)
Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.120) (2013) (0)
Natural killer cell status in multiple sclerosis and its association with interferon beta-1a treatment (2009) (0)
Comparative utility of different progression metrics in PPMS: re-analysis of the PROMiSe clinical trial dataset (P7.237) (2015) (0)
NewsSpeak: taking the piss ... Prof G loses all credibility (2015) (0)
Selective targeting of spasticity by CNS-excluded cannabinoids (2011) (0)
Subtle blood brain barrier leakage in non-enhancing lesions in relapsing multiple sclerosis: multi-centre study of patients in a therapeutic trial (2005) (0)
Linking X to MS: Immunity and demyelination on the X-chromosome in MS. (2022) (0)
Vaccine hesitancy in people with multiple sclerosis (2022) (0)
PO151 Infections in patients with multiple sclerosis on alemtuzumab – should antibiotic prophylaxis be standard? (2017) (0)
199 Changes in natalizumab exposure and PML incidence over time (2019) (0)
Neutralising antibodies to interferon beta are associated with loss of efficacy of treatment and reduced side effects (2007) (0)
Prevalence of disability improvement in relapsing–remitting multiple sclerosis patients treated with cladribine tablets (2022) (0)
The Impact of Socioeconomic Status on Treatment Choice in Patients with Multiple Sclerosis. (P2.346) (2018) (0)
Corrigendum to “Soluble adhesion molecules in Gilles de la Tourette's syndrome” [J Neurol Sci 234 (2005) 79–85] (2006) (0)
PO128 Infusion-related reactions with ocrelizumab in rms and ppms (2017) (0)
Improving estimation of Parkinson’s disease risk—the enhanced PREDICT-PD algorithm (2021) (0)
Editors׳ welcome. (2015) (0)
Selective and Discontinuous Reduction of B and T Lymphocytes and NK Cells in Patients with Early and Relapsing MS (ORACLE-MS, CLARITY and CLARITY Extension) after Administration of Cladribine Tablets (P5.351) (2018) (0)
PO127 Composite confirmed disability progression in oratorio (2017) (0)
Swelling of the Outer Retinal Layers in Acute Optic Neuritis (P4.042) (2015) (0)
Natalizumab reduces loss of visual function in patients with relapsing multiple sclerosis (2006) (0)
Editors' Welcome. (2015) (0)
Oral Cladribine and Fingolimod for Relapsing Multiple Sclerosis REPLY (2010) (0)
091 Evaluation of remote assessments for multiple sclerosis in a real-world setting (2022) (0)
120 An algorithm to identify individuals at high-risk of Parkinson's disease in the community (2012) (0)
Editors׳ welcome. (2014) (0)
Immunological parameters in blood as surrogate markers in multiple sclerosis (2001) (0)
Editors' welcome. (2015) (0)
Effect of teriflunomide on Epstein-Barr virus shedding in relapsing-remitting multiple sclerosis patients: Outcomes from a real-world pilot cohort study. (2022) (0)
Testing neutralizing antibodies: The way ahead (2007) (0)
Delayed Signs of Early Disability Progression After 8.5 Years of Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis (S46.003) (2023) (0)
VSN16R a novel agent for the control of spasticity (2011) (0)
High resolution 1H nuclear magnetic resonance spectroscopic-based metabolomic urine analysis of experimental autoimmune encephalitis, a model disease of multiple sclerosis (2008) (0)
212 Is there an ethnicity bias of access to MS services? The barts health experience revisited (2019) (0)
Reply (2014) (0)
Modifiable Risk Factors for Multiple Sclerosis are Consistent Across Diverse Ethnic Backgrounds: A Nested Case-Control Study in a UK Population-Based Cohort (2022) (0)
Antibasal ganglia antibodies in atypical dystonia and tics: A prospective study (2004) (0)
Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary. (2022) (0)
Sustained Improvement in Disability Outcomes with Alemtuzumab in Active Relapsing-Remitting Multiple Sclerosis Patients Who Participated in CARE-MS II: Three-year Follow-up (P3.165) (2014) (0)
Optic nerve functional properties in MOGTCR mice with induced optic neuritis (2014) (0)
Rationale For Advancing Laquinimod For Progressive MS: Evidence From Large Clinical Trials In RRMS (S4.001) (2014) (0)
Update on NHS Reset and Reform achievements in 2021 (2022) (0)
Editors' Welcome. (2018) (0)
Multi-stakeholder Colloquium – Opportunities and Challenges in Multiple Sclerosis Management (2016) (0)
The incidence and clinical significance of antibodies to natalizumab: 2-year results from the AFFIRM study (2005) (0)
The effect of natalizumab on brain atrophy and its relationship with cognitive function in multiple sclerosis (2006) (0)
020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years (2022) (0)
Sa.32. The Immunogenicity of Natalizumab in Patients with Multiple Sclerosis (2006) (0)
Impaired energy metabolism and increased lipid peroxidation in multiple sclerosis (2006) (0)
Effect of interferon beta and the development of neutralising antibodies, on reactivation of latent EBV, in patients with multiple sclerosis (2008) (0)
PO10-TU-33 Development of a new formulation of subcutaneous interferon beta-1a for relapsing-remitting multiple sclerosis: efficacy, safety and immunogenicity results from a comprehensive pre-clinical and clinical trial series (2009) (0)
143 Effect of siponimod on disability progression measured by ambulation score: post hoc analysis of EXPAND (2022) (0)
One size doesn't fit all. (2019) (0)
A randomized, double-blind, parallel-group, placebo-controlled Phase 3 trial to evaluate efficacy and safety of ocrelizumab in PPMS (2016) (0)
Consistent reductions in MRI activity with cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis in the CLARITY study (2010) (0)
Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary. (2022) (0)
In Clarity the Severity and Frequency of Relapses are Lower in Patients with Relapsing-remitting Multiple Sclerosis Treated with Cladribine Tablets Versus Placebo (2018) (0)
178 Atraumatic lumbar puncture campaign – effect on complications (2022) (0)
Dermatitis herpetiformis, coeliac disease, and neurological dysfunction (2002) (0)
Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy (2023) (0)
Clinical neuroimmunology, second edition, 2005 (2006) (0)
No evidence for an association between alcohol consumption and Multiple Sclerosis risk: a UK Biobank study (2022) (0)
OPL114 The effects of baseline disease activity on magnetic resonance imaging (MRI) outcomes in the AFFIRM study (2005) (0)
British specialist multiple sclerosis centre Interferon beta in multiple sclerosis: experience in a (2008) (0)
Late Breaking News (2015) (0)
Increased Urinary Neopterin Excretion in Vaccinated Adults (1996) (0)
Immunology in movement disorders: PANDAS and Tourette's: YES (2004) (0)
The first on the stage: cladribine (2010) (0)
FP33-WE-03 Effects of natalizumab treatment on sustained improvement in physical disability and quality of life in patients with relapsing multiple sclerosis (2009) (0)
Inactive or moderately active human promoters are enriched for inter-individual epialleles (2013) (0)
Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary. (2022) (0)
Editors' Welcome. (2017) (0)
CLINICAL VIEWPOINT: Immunosuppression and COVID-19 (2020) (0)
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence. (2022) (0)
PO135 Cladribine tablets in rrms: lymphocyte counts (2017) (0)
097 Transcranial sonography in the prodromal phase of PD (2022) (0)
Why should Neurologists get involved in family planning? (2020) (0)
measures 1-year smartphone study in multiple sclerosis (2015) (0)
Derisking CD20-therapies for long-term use (2021) (0)
192 Does socioeconomic status impact on the prescription of disease-modifying treatments in people with multiple sclerosis? (2019) (0)
WED 186 Effect of cladribine tablets on immune cells in patients with ms (2018) (0)
125 Towards an optimal multiple sclerosis patient case-load for a full-time MSologist (2022) (0)
ELEVATED SALIVARY DJ-1 IN PARKINSON'S DISEASE IS ASSOCIATED WITH ALTERED SALIVARY SECRETION (2015) (0)
Editors' Welcome. (2016) (0)
Inequality in accessing healthcare for people with MS. (2023) (0)
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets (2021) (0)
Clinical Efficacy Is Sustained in Relapsing Remitting Multiple Sclerosis Following Treatment Switch to Placebo from Cladribine Tablets in Patients with High Disease Activity at Baseline (2018) (0)
Expert Opinion on the Use of Cladribine Tablets in Clinical Practice for the Treatment of Relapsing Multiple Sclerosis (2020) (0)
The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination (2022) (0)
163 Development of clinical and patient-reported quality metrics for multiple sclerosis: a UK pilot study report (2019) (0)
Detecting and predicting neutralization of alemtuzumab responses in multiple sclerosis (2020) (0)
Incorporation of Other Biomarkers (2007) (0)
Multiple Sclerosis Therapeutics: Cladribine to treat multiple sclerosis (2011) (0)
WED 184 Cladribine tablets in clarity patients with high disease activity ms (2018) (0)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Laquinimod 0.6mg or 1.2mg QD versus IFNβ-1a in Patients with Relapsing Remitting Multiple Sclerosis (P3.153) (2014) (0)
048 Postprandial somnolence in people with multiple sclerosis (2022) (0)
NEUTRALISING ANTIBODIES TO INTERFERON–BETA PREDICT CONVERSION TO SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS IN PATIENTS WITH MULTIPLE SCLEROSIS (2013) (0)
Authors' Reply (1998) (0)
Evaluation of anti-interferon beta neutralising antibodies in subjects with relapsing multiple sclerosis (2007) (0)
Benefits of the serum-free formulation of interferon beta-1a: Lessons from clinical trials (2010) (0)
Editors' welcome. (2015) (0)
Editors' welcome. (2017) (0)
Editors' Welcome. (2015) (0)
Design of the RECORD MS study and pregnancy registry in patients with multiple sclerosis receiving cladribine tablets therapy in normal medical care (2011) (0)
Effects of Fingolimod on MRI Outcomes in Patients with Pediatric Onset Multiple Sclerosis: Results from Phase 3 PARADIGMS Study (S51.005) (2018) (0)
Posters on Display (2019) (0)
Efficacy of cladribine tablets 3.5 mg/kg in patients with relapsing multiple sclerosis aged above and below 45 years; clarity and clarity extension (2019) (0)
"Rocking the boat" with a new drug for neuromyelitis optica spectrum disorder. (2020) (0)
119 A pilot study of an algorithm designed to identify Parkinson's disease in the early, non-motor phase (2011) (0)
OCRELIZUMAB IN PRIMARY PROGRESSIVE MS: THE ORATORIO STUDY (2016) (0)
Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2007) (0)
Contents Vol. 32, 2009 (2009) (0)
121 The ADAMS project: protocol and baseline results (2022) (0)
The unintended consequences of NICE (2018) (0)
Missed MS or MIMS not prodromal MS: Expanding the diagnostic MS spectrum. (2021) (0)
PO150 Memory b cells are key for immunotherapy in multiple sclerosis (2017) (0)
Accelerated axonal degeneration after bonemarrow transplantation for aggressive multiple sclerosis (2006) (0)
Acute flaccid myelitis in the 21st century: reminiscence of poliomyelitis or a new emergent disease. (2019) (0)
Editors' Welcome. (2017) (0)
Toward better diagnosis of progressive supranuclear palsy: Cerebrospinal fluid biomarkers (2004) (0)
1639 Acquired copper deficiency mimicking sub acute combined degeneration of the spinal cord (2005) (0)
147 Siponimod preserves retinal thickness: findings from the EXPAND OCT substudy (2022) (0)
PO124 Validation of an environmentally-friendly and affordable cardboard 9-hole peg test (2017) (0)
Corrigendum to 'Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (2014) 1958-1971]. (2018) (0)
Serum levels of 25-hydroxy vitamin D in normal Biozzi and C57BL/6 mice and during the course of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE) (2013) (0)
Association of Serum Neurofilament Light Chain with Cognitive and Disability Measures in Patients with Very Early MS: A Longitudinal Study (P1.396) (2016) (0)
Melatonin and multiple sclerosis. (2021) (0)
ALEMTUZUMAB IMPROVES EDSS FUNCTIONAL SYSTEMS SCORES IN RRMS (2016) (0)
Editors' Welcome. (2017) (0)
Understanding Conflicting Neuropathological Findings in Patients Clinically Diagnosed as Having (2017) (0)
Movement disorder in Whipple's disease (2001) (0)
Editors' Welcome. (2018) (0)
060 Association of brain volume loss and neda outcomes in patients with relapsing multiple sclerosis in the opera i and opera ii studies (ENCORE) (2018) (0)
Delayed-release Dimethyl Fumarate Demonstrates Long-term, Sustained Efficacy in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis followed for at least Eight-Years (P6.382) (2018) (0)
Disease specific cerebrospinal fluid investigations (2011) (0)
Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids (2014) (0)
Two-Year Interim Analysis of Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Delayed-Release Dimethyl Fumarate in the ENDORSE Study (P4.178) (2014) (0)
OCT, Visual Function and MRI Measures in Acute Optic Neuritis: Baseline Data from a Clinical Trial (P2.255) (2014) (0)
The effects of natalizumab on disability and health-related quality of life in patients with relapsing MS (2006) (0)
Response: Treatment of multiple sclerosis as a single disease based on the body-pathology-environment model. (2022) (0)
PO111 Daclizumab efficacy in highly active rrms: select/decide (2017) (0)
Neuroleukin, a potential antigenic target in paediatric Opsoclonus/Myoclonus syndrome (OMS) (2004) (0)
Cannabinoid-mediated immunosuppression in experimental allergic encephalomyelitis (2006) (0)
Development of an ELISA for sensitive quantification of three-repeat and four-repeat tau isoforms in tauopathies and characterisation of tau isoforms in CSF (2006) (0)
Is multiple sclerosis disease activity, as detected by gadolinium-enhanced MRI, associated with virological and immunological evidence of EBV reactivation in the peripheral blood? (2008) (0)
141 Cognitive processing speed predicts disease progression in SPMS: post hoc analysis from the EXPAND study (2022) (0)
Emerging disease modifying treatments-A therapeutics update from ECTRIMS/ACTRIMS, Amsterdam, 2011. (2012) (0)
PO114 Neda achievement by time interval with daclizumab (2017) (0)
Editors' welcome. (2012) (0)
Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis (2013) (0)
Editors' Welcome. (2016) (0)
Multiple types of relapses in MOG antibody disease. (2023) (0)
Clinical application of vanadium-based assay for the detection of nitrite/nitrate in human body fluids (2002) (0)
Effects of Daclizumab HYP on Accumulation of Disability Exclusive of Acute Relapse in Moderately/Severely Disabled Relapsing-Remitting Multiple Sclerosis Patients: Neurophysical Composite Outcome from the DECIDE Study (P3.085) (2016) (0)
Evaluation of Immunogenicity in Multiple Sclerosis Patients Treated with Daclizumab-HYP During the SELECT and SELECTION Clinical Trials (P3.177) (2014) (0)
Neuroprotection with phenytoin in acute optic neuritis: results of a phase II randomised controlled trial. (2015) (0)
178 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis (2019) (0)
The biological rabbit hole: Only for the blind. (2022) (0)
Editors' Welcome. (2016) (0)
CP3 Progressive ataxia with unusual radiographic findings (2010) (0)
Natalizumab Reduces Total Disability Burden Relative to Placebo in Patients with Relapsing-Remitting Multiple Sclerosis Regardless of the Occurrence of Relapses or Confirmed Disability Progression or Improvement over 2 Years in the AFFIRM Study (P7.244) (2015) (0)
Efficacy and Safety of Existing and Emerging Monoclonal Antibody Therapies for Multiple Sclerosis (2016) (0)
Promoting regeneration and repair in Multiple Sclerosis. (2013) (0)
Chronic-relapsing varicella zoster meningitis - Successfully treated with varicella vaccine. (2019) (0)
Only longer follow up will do (2017) (0)
The Sylvia Lawry Centre for Multiple Sclerosis Research (SLCMSR)--Critical review facing the 20 anniversary. (2022) (0)
Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1β (2017) (0)
Focused Workshops (2018) (0)
101 Motor and non-motor features of prodromal PD (2022) (0)
096 Motor and non-motor features of prodromal Parkinson’s in idiopathic anosmia (2022) (0)
Referat – Daclizumab High-Yield Process bei schubförmiger Multiple Sklerose (2014) (0)
Editors׳ welcome. (2014) (0)
Editors' welcome. (2014) (0)
DACLIZUMAB HYP VS IM INTERFERON BETA-1A IN MS: NEDA RESULTS FROM DECIDE (2016) (0)
Cognition and its relation to brain health in patients with MS: Response to letter (2020) (0)
Development of Rebif (R) New Formulation for MS treatment: consolidated results from preclinical and phase I studies (2007) (0)
P2-155 Development of sensitive and specific ELISAs for three-repeat and four-repeat tau isoforms (2006) (0)
PO149 A new perspective on autoimmunity after alemtuzumab (2017) (0)
The distribution of alpha-synuclein in the enteric nervous system: An immunohistochemical study on colonic resections from 24 control and 4 Parkinson's disease patients (2014) (0)
▼Natalizumab for multiple sclerosis? (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Gavin Phd Giovannoni?

Gavin Phd Giovannoni is affiliated with the following schools:

Gavin Phd Giovannoni's Academic­Influence.com Rankings

Why Is Gavin Phd Giovannoni Influential?

Gavin Phd Giovannoni's Published Works

Published Works

What Schools Are Affiliated With Gavin Phd Giovannoni?

Gavin Phd Giovannoni's AcademicInfluence.com Rankings